Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
The research team led by Alexander Eggermont, MD, PhD, of the Gustave Roussy Cancer Campus Grand Paris, found that among over 1,000 stage III patients with melanoma treated…
Working with the theory that it would be possible to detect immune reinvigoration related to disease-free survival in various stages of melanoma, lead investigator Alexander C. Huang, MD,…
After prior case studies showed promising results with PD-1 inhibition followed by chemotherapy, a group of doctors, led by Georgia Sofia Karachaliou, MD, MSc, of the Department of Medicine…
A new analysis published in European Urology suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA,…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality…
